Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Inclusion Criteria: * Histologically confirmed malignant solid tumor, including the following: * Osteosarcoma * Ewing sarcoma/peripheral primitive neuroectodermal tumor * Rhabdomyosarcoma * Neuroblastoma * Wilms tumor * Synovial sarcoma * Hepatoblastoma * Adrenocortical carcinoma * Retinoblastoma * No known curative therapy or therapy proven to prolong survival with an acceptable quality of life exists * Radiographically measurable disease\*, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by MRI or CT scan or ≥ 10 mm by spiral CT scan * The following are not considered measurable disease: * Ascites, pleural effusions, or other malignant fluid collections * Bone marrow infiltration by tumor * Lesions detected only by non-MIBG nuclear medicine studies (e.g., bone scan) * Previously irradiated lesions that have not demonstrated clear progression post-radiotherapy * No known Central Nervous System (CNS) metastases unless they were treated by surgery or radiotherapy AND are stable with no recurrent lesions for ≥ 3 months * Lansky or Karnofsky performance status (PS) 50-100% OR Eastern Cooperative Oncology Group (ECOG) PS 0-2 * Absolute neutrophil count (ANC) ≥ 1,000/mm³ (\> 250/mm³ for patients with neuroblastoma) * Platelet count ≥ 75,000/mm³ (\> 25,000/mm³ for patients with neuroblastoma) (transfusion independent) * Hemoglobin ≥ 8.0 g/dL (≥ 7.5 g/dL for patients with neuroblastoma) (RBC transfusion allowed) * Creatinine clearanc…